Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.
Bristol-Myers Squibb Company
C C C
C12Q C12Q C12Q
additional additional inventional
Douglas Michael Jiwen Ashok Ramesh Fei Rameh Gayle M. Warren Marco M. Xia Ricardo M. Joan M.
Robinson Chen Dongre Huang Hafezi Wittenberg Hurlburt Gottardis Han Attar Carboni